EJMI. 2022; 6(2): 259-265 | DOI: 10.14744/ejmi.2022.10130

Predictive Value of Lymphocyte-Related Blood Parameters of before Ado-Trastuzumab Emtansin Treatment in Breast Cancer

Gulcan Bulut¹, Ahmet Ozveren², Ferhat Ekinci³, Cengiz Yilmaz⁴, Serkan Yildirim⁵, Atike Pinar Erdogan^3
1Division of Medical Oncology, International Medicana Hospital, Izmir, Turkey, ²Division of Medical Oncology, Kent Hospital, Izmir, Turkey, ³Department of Internal Medicine, Division of Medical Oncology, Celal Bayar University Faculty of Medicine, Manisa, Turkey, ⁴Division of Medical Oncology, Bozyaka Training and Research Hospital, Izmir, Turkey, ⁵Department of Internal Medicine, Division of Medical Oncology, Başkent University Hospital, Konya, Turkey

The overall survival of metastatic HER2-positive breast cancer has been prolonged with treatment variability recently. Ado-Trastuzumab Emtansine ( TDM1) has been used in the treatment of HER2 metastatic breast cancer after FDA approval as an antibody-drug conjugate. Some markers may be predictive for clinician in the man-agement of this TDM1 therapy. There is a need for simple and cost-effective markers to show the treatment re-sponse. The primary aim of this study is to establish a correlation between progression free survival and pre-treatment hematological inflammatory parameters [absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR)] in advance breast cancer. The secondary aim of the study is to bring the markers that predict response to treatment from hematological parameters to the literature

---

Cite This Article

Bulut G, Ozveren A, Ekinci F, Yilmaz C, Yildirim S, Erdogan A. Predictive Value of Lymphocyte-Related Blood Parameters of before Ado-Trastuzumab Emtansin Treatment in Breast Cancer. EJMI. 2022; 6(2): 259-265

Corresponding Author: Gulcan Bulut

Full Text PDF PDF Download